Quell Therapeutics

About Quell Therapeutics

Quell Therapeutics is a pioneering biotechnology company based in the UK, dedicated to developing innovative therapies for patients with severe autoimmune diseases and other serious conditions. Our mission is to harness the power of the immune system to create transformative treatments that improve patient outcomes and quality of life.

At Quell, we focus on advancing our proprietary platform technology, which enables the development of engineered T cell therapies. These therapies are designed to specifically target and modulate the immune response, offering a new approach to treating complex diseases that currently have limited treatment options.

Our team comprises leading scientists, clinicians, and industry experts who are committed to pushing the boundaries of medical science. We collaborate with academic institutions and research organisations to ensure that our therapies are grounded in the latest scientific advancements.

Quell Therapeutics is driven by a strong commitment to patient-centricity. We actively engage with patients and healthcare professionals to understand their needs and incorporate their feedback into our research and development processes.

As we continue to grow, we aim to expand our pipeline of therapies and explore new indications for our technologies. Our vision is to become a leader in the field of immunotherapy, providing hope to patients worldwide.

• Innovative Therapies: Focused on autoimmune diseases and serious conditions.
• Proprietary Technology: Engineered T cell therapies targeting immune modulation.
• Expert Team: Comprising scientists, clinicians, and industry leaders.
• Patient-Centric Approach: Engaging with patients to inform our R&D.

With a robust pipeline and a commitment to excellence, Quell Therapeutics is poised to make significant contributions to the field of biotechnology and improve the lives of patients around the globe.